DNLI stock forecast, quote, news & analysis
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases... Show more
Why Denali Therapeutics (DNLI) Is Down -14% in the Last 30 Days
Key Takeaways
- DNLI stock declined -14% over the past 30 days amid volatile trading, despite a major FDA approval for its Hunter syndrome drug AVLAYAH on March 25, followed by profit-taking and recent sharp drops.
- Over the past quarter, shares rose +10%, driven by anticipation of regulatory milestones and positive Q4 earnings beat in late February.
- Key drivers include FDA accelerated approval validating the Transport Vehicle platform, narrower-than-expected Q4 losses, and analyst upgrades, offset by post-approval selloffs and biotech sector sentiment.
- Upcoming commercial launch of AVLAYAH and confirmatory trial data remain critical catalysts.
Denali Therapeutics (DNLI) Company Overview and Market Position
Denali Therapeutics Inc. (DNLI) is a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases and lysosomal storage disorders. Its core business model revolves around the proprietary Transport Vehicle (TV) platform, which enables therapeutics to cross the blood-brain barrier, addressing a major challenge in central nervous system drug delivery. Operating in the competitive biotech industry, Denali differentiates itself through collaborations with partners like Biogen and focuses on genetically validated targets. Competitors include Biogen (BIIB), Roche, and AbbVie. These fundamentals, particularly pipeline progress in rare diseases like Hunter syndrome, directly underpin recent stock price volatility tied to clinical and regulatory advancements.
Denali Therapeutics (DNLI) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, DNLI stock fell -14%, from a close of $21.18 on February 27 to $18.16 on March 27. The movement was highly volatile, featuring a surge to a 52-week high near $23.77 amid FDA anticipation, followed by profit-taking and steep declines, including -8% on March 27. Trading volume spiked on key news days, indicating event-driven swings rather than steady trends.
In contrast, the past quarter saw shares rise +10%, from around $16.58 in late December to the current level. Performance was trend-driven upward, supported by pipeline updates, though punctuated by biotech sector pressures. The stock outperformed the broader industry in longer-term metrics like 1-year returns of +28%.
What Drove DNLI Stock Price in the Last 30 Days
The 30-day decline masked significant catalysts. The standout event was the U.S. FDA's accelerated approval of AVLAYAH (tividenofusp alfa-eknm) on March 25 for neurologic manifestations of Hunter syndrome, the first such therapy to cross the blood-brain barrier. Shares jumped +7% that day to $22.47, validating Denali's TV platform and earning a Rare Pediatric Disease Priority Review Voucher. Subsequent profit-taking led to a -5.7% drop on March 26 and further selling, amplified by high volatility and lower volume. Earlier, Q4 2025 earnings on February 26 beat expectations with a -$0.73 EPS loss versus -$0.75 forecast, highlighting launch readiness, but failed to sustain gains amid rising operating expenses. Analyst upgrades post-approval, like Goldman Sachs raising targets to $40, provided support but couldn't counter short-term sentiment shifts in biotech.
What Drove DNLI Stock Performance Over the Last Quarter
The quarterly +10% gain reflected sustained momentum from pipeline advancements and financial stability. January 6 guidance emphasized 2026 priorities, including the Hunter syndrome PDUFA (originally April 5, accelerated to March approval). Q4 results showed $966 million cash reserves, funding operations into 2028 despite net losses widening to $512.5 million annually due to R&D investments. Institutional interest grew, with the stock outperforming the biotech sector (+11.6% six-month gain versus industry). Macro factors like interest rate expectations aided growth stocks, while sector trends in rare disease therapies bolstered positioning against competitors. Cumulative impact stemmed from regulatory optimism overriding expense pressures.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots out of hundreds that analyze thousands of tickers across various markets. These curated bots employ diverse strategies, such as trend-following, mean reversion, or momentum trading, across short-term intraday to long-term horizons. Performance metrics like win rate, profit factor, and Sharpe ratio highlight their edge, with regular updates reflecting real-time market adaptation. Investors can explore, backtest, and deploy these bots to enhance stock analysis and automate trades. Check the Trending AI Robots page to discover bots tailored for volatile biotech names like DNLI.
DNLI Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor AVLAYAH's U.S. commercial launch, including uptake among ~500 prevalent Hunter syndrome patients and pricing dynamics. Confirmatory Phase 2/3 COMPASS trial data will verify clinical benefit for full approval. Upcoming Q1 2026 earnings around May 5 offer pipeline updates on TV-enabled programs for other lysosomal disorders and neurodegeneration. Broader biotech trends, FDA voucher monetization, and macro factors like interest rates could sway sentiment. Risks include trial setbacks or launch delays, while catalysts encompass partnerships or data readouts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
DNLI's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for DNLI turned positive on May 26, 2026. Looking at past instances where DNLI's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 27, 2026. You may want to consider a long position or call options on DNLI as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
DNLI moved above its 50-day moving average on June 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DNLI crossed bullishly above the 50-day moving average on June 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 158 cases where DNLI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DNLI broke above its upper Bollinger Band on June 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.122) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). DNLI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). DNLI's P/S Ratio (3333.333) is very high in comparison to the industry average of (367.026).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company
Industry Biotechnology